탄산란탄
Lanthanum Carbonate
Lanthanum carbonate (octa-hydrate)
다른 이름: Fosrenol · Lantharenol · Renalzin · Bay-78-1887 · Lanthanum
VetSheet 수의사 팀 검수업데이트 2026년 4월 5일근거 기반 수의학 참고자료
용량은 수의사 전문가를 위한 임상 참고자료입니다. 반드시 최신 약물 정보 및 개별 환자에 따라 확인하시기 바랍니다.
동물 종별 용량
🌎 NA — North America🌍 EU — Europe
개
| 적응증 | 용량 | 경로 | 빈도 | 기간 | 지역 |
|---|---|---|---|---|---|
| Chronic kidney disease (Hyperphosphataemia) | 100 mg/kg/day | PO | divided between meals | Chronic | 🌍 EU |
- Chronic kidney disease (Hyperphosphataemia): Dose adjustments should be based on serum phosphate levels monitored at 4-6 week intervals.
고양이
| 적응증 | 용량 | 경로 | 빈도 | 기간 | 지역 |
|---|---|---|---|---|---|
| Phosphate binder | 200 mg (total dose) PO (on/in food) 2-3 times daily. | PO | 2-3 times daily | — | 🌎 NA |
| Phosphate binder (using Renalzin) | 2 mLs (400 mg) applied in the cat's food, once or twice daily depending on the cat's feeding regimen. | PO | once or twice daily | — | 🌎 NA |
| Chronic kidney disease (Hyperphosphataemia) | 400-800 mg/cat/day | PO | divided according to feeding schedule (give some with every meal) | Chronic | 🌍 EU |
- Phosphate binder: Anecdotally appears safe and effective.
- Chronic kidney disease (Hyperphosphataemia): Recommended starting dose is 400 mg per day. It is important to give some with every meal.
용량은 수의사 전문가를 위한 임상 참고자료입니다. 반드시 최신 약물 정보 및 개별 환자에 따라 확인하시기 바랍니다.
개요
탄산란탄은 주로 말기 신질환(ESRD) 환자의 고인산혈증을 관리하는 데 사용되는 경구용 인 결합제입니다.
식이 인 제한이 만성 신장 질환(CKD) 관리의 기본이지만, 식이요법만으로 불충분하거나 환자가 처방식을 거부할 때 인 결합제가 지시됩니다.
임상 요점: 칼슘 기반 결합제(고칼슘혈증 유발 가능)나 알루미늄 기반 결합제(장기 사용 시 알루미늄 독성 위험)와 달리, 란탄은 칼슘과 알루미늄을 포함하지 않아 수의 임상에서 고인산혈증의 장기 관리에 매력적인 선택지입니다.
작용 기전
Lanthanum carbonate acts locally in the gastrointestinal tract.
- It dissociates in the acidic environment of the upper GI tract (stomach) to release lanthanum ions (La³⁺).
- These ions bind to dietary phosphate → forming highly insoluble lanthanum phosphate complexes.
- These complexes cannot cross the intestinal mucosa and are subsequently eliminated in the feces, thereby reducing net intestinal absorption of phosphorus.
안전성·주의사항
금기사항
- Patients with non-intact GI tract (e.g., GI ulcers, colitis) - use with caution due to increased risk of systemic absorption
- Acute renal crisis (patients should be stabilized first)
부작용
- Inappetence
- None known according to the monograph
- Gastrointestinal upset (nausea, vomiting, diarrhea, or constipation) may occur (Clinical Pearl)
주의
There are no listed absolute contraindications, but it should be used with caution in patients where the GI tract is not intact (e.g., GI ulcers, colitis) as there is an increased chance for oral absorption. Safe for use during pregnancy and nursing.
약물 상호작용
Potential decreased absorption; separate dosing by 2 hours
Potential decreased absorption; separate dosing by 2 hours
Potential decreased absorption; separate dosing by 2 hours
Potential decreased absorption; separate dosing by 2 hours
Potential decreased absorption; separate dosing by 2 hours
Potential decreased absorption; separate dosing by 2 hours
Potential decreased absorption; separate dosing by 2 hours
Potential decreased absorption; separate dosing by 2 hours
Potential decreased absorption; separate dosing by 2 hours
Potential decreased absorption; separate dosing by 2 hours
Potential decreased absorption; separate dosing by 2 hours
Potential decreased absorption; separate dosing by 2 hours
Potential decreased absorption; separate dosing by 2 hours
Lanthanum may bind to other drugs in the GI tract, reducing their absorption. Should be given at least 1 hour before or 3 hours after other medications.
모니터링
- Serum phosphorous
- Serum potassium
- Serum bicarbonate
- Serum chloride
- Serum phosphate levels (at 4-6 week intervals to adjust dosage and achieve target concentrations)
- Renal parameters (BUN, Creatinine, SDMA)
- Serum calcium levels
약동학
반감기
흡수
Following oral doses, lanthanum bioavailability is very low (less than 0.002%).
분포
Systemically available lanthanum is very highly bound to plasma proteins (>99%). Tissue levels increase over time and can be several orders of magnitude higher than plasma levels. Highest levels found in GI tract, bone, and liver.
대사
Not metabolized. It is an inorganic salt.
배설
Absorbed lanthanum is cleared primarily via biliary excretion into the feces. In dogs, mean recovery of an oral dose averages 94%.
과다투여
No specific information located, but acute overdose is likely tolerated with potential for GI effects. Only supportive treatment should be required. In cats, oral dosages up to 1 gram/kg were tolerated, but repeated vomiting occurred at 2 grams/kg.
제품
제형
- Chewable tablets
- Pump gel/paste
- 500 mg chewable tablet
- 750 mg chewable tablet
- 1 g chewable tablet
동물용의약품
- Renalzin (lanthanum carbonate, kaolin, vitamin E) pump gel/paste (200 mg/mL) - Available in some countries outside USA/Canada
- Lantharenol (General sale / Feed additive - availability varies)
인용의약품
- Fosrenol Oral Chewable Tablet 500 mg, 750 mg, & 1,000 mg
- Fosrenol 500 mg chewable tablets
- Fosrenol 750 mg chewable tablets
- Fosrenol 1 g chewable tablets
규제 현황
Fosrenol is POM; Lantharenol has been marketed as a general sale feed additive.
Fosrenol is POM; Lantharenol has been marketed as a general sale feed additive.
규제 데이터 없음: 🇺🇸 US · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
보관·안정성
Store tablets at room temperature (25°C, 77°F); excursions are permitted to 15°-30°C (59°-86°F). Protect from moisture.
보호자 정보
- 투여 방법: 동물이 알약을 통째로 삼키게 하지 마십시오. 알약을 부수어 동물의 사료와 골고루 섞어주십시오.
- 투여 시간: 사료에 있는 인과 결합할 수 있도록 반드시 식사와 함께 투여하는 것이 중요합니다.
- 상용 수의학 제품: 특정 수의용 겔/페이스트를 사용하는 경우 라벨에 제공된 정확한 투여 지침을 따르십시오.
- 부작용: 구토나 식욕 부진이 있는지 관찰하고, 이러한 증상이 나타나면 수의사에게 연락하십시오.
VetSheet 의약품 참고자료는 수의사 전문가의 임상 의사결정 지원을 위한 것이며, 전문적 판단이나 제조사의 최신 약물 정보를 대체할 수 없습니다.